Cargando…

Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex

mTORC1 is aberrantly activated in cancer and in the genetic tumor syndrome tuberous sclerosis complex (TSC), which is caused by loss-of-function mutations in the TSC complex, a negative regulator of mTORC1. Clinically approved mTORC1 inhibitors, such as rapamycin, elicit a cytostatic effect that fai...

Descripción completa

Detalles Bibliográficos
Autores principales:	McNamara, Molly C., Hosios, Aaron M., Torrence, Margaret E., Zhao, Ting, Fraser, Cameron, Wilkinson, Meghan, Kwiatkowski, David J., Henske, Elizabeth P., Wu, Chin-Lee, Sarosiek, Kristopher A., Valvezan, Alexander J., Manning, Brendan D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663903/ https://www.ncbi.nlm.nih.gov/pubmed/36388985 http://dx.doi.org/10.1016/j.isci.2022.105458

Ejemplares similares

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2014)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment
por: Tang, Yan, et al.
Publicado: (2022)

Raptor Preys on mTOR Imbalance in Tuberous Sclerosis
por: Ramamurthy, Aishwarya, et al.
Publicado: (2023)

The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals
por: Torrence, Margaret E, et al.
Publicado: (2021)

Is mTOR inhibition a systemic treatment for tuberous sclerosis?
por: Moavero, Romina, et al.
Publicado: (2013)

Perfect match: mTOR inhibitors and tuberous sclerosis complex
por: Luo, Cong, et al.
Publicado: (2022)

Butyrate dictates ferroptosis sensitivity through FFAR2-mTOR signaling
por: Wang, GuoYan, et al.
Publicado: (2023)

YAP enters the mTOR pathway to promote tuberous sclerosis complex
por: Liang, Ning, et al.
Publicado: (2015)

Lysosomal regulation of cholesterol homeostasis in tuberous sclerosis complex is mediated via NPC1 and LDL-R
por: Filippakis, Harilaos, et al.
Publicado: (2017)

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
por: Courtwright, Andrew M., et al.
Publicado: (2017)

mTOR Signaling and Neural Stem Cells: The Tuberous Sclerosis Complex Model
por: Polchi, Alice, et al.
Publicado: (2018)

Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis
por: Pollizzi, Kristen, et al.
Publicado: (2009)

Percutaneous cryoablation for tuberous sclerosis-associated renal angiomyolipoma with neoadjuvant mTOR inhibition
por: Krummel, Thierry, et al.
Publicado: (2014)

Timing of mTOR activation affects tuberous sclerosis complex neuropathology in mouse models
por: Magri, Laura, et al.
Publicado: (2013)

The Putative Role of mTOR Inhibitors in Non-tuberous Sclerosis Complex-Related Epilepsy
por: Goldstein, Hannah E., et al.
Publicado: (2021)

RARE-25. RETINAL ASTROCYTOMA mTOR INHIBITOR THERAPY IN TUBEROUS SCLEROSIS MOSAICISM
por: Evans, Naomi, et al.
Publicado: (2020)

AAA + ATPase Thorase inhibits mTOR signaling through the disassembly of the mTOR complex 1
por: Umanah, George K. E., et al.
Publicado: (2022)

Hierarchical Phosphorylation of HOXB13 by mTOR Dictates Its Activity and Oncogenic Function in Prostate Cancer
por: Chen, Yonghong, et al.
Publicado: (2023)

Potential of mTOR inhibitors for the treatment of subependymal giant cell astrocytomas in tuberous sclerosis complex
por: Major, Philippe
Publicado: (2011)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex
por: Palavra, Filipe, et al.
Publicado: (2017)

Tuberous Sclerosis Complex as Disease Model for Investigating mTOR-Related Gliopathy During Epileptogenesis
por: Zimmer, Till S., et al.
Publicado: (2020)

The TSC-mTOR pathway regulates macrophage polarization
por: Byles, Vanessa, et al.
Publicado: (2013)

Therapeutic Trial of Metformin and Bortezomib in a Mouse Model of Tuberous Sclerosis Complex (TSC)
por: Auricchio, Neil, et al.
Publicado: (2012)

Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex
por: Zhang, Bo, et al.
Publicado: (2013)

Treatment effect of mTOR-inhibition on tissue composition of renal angiomyolipomas in tuberous sclerosis complex (TSC)
por: Brakemeier, Susanne, et al.
Publicado: (2017)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Treatment of Cardiac Rhabdomyomas with mTOR Inhibitors in Children with Tuberous Sclerosis Complex—A Systematic Review
por: Sugalska, Monika, et al.
Publicado: (2021)

Generalized Negative Reciprocity in the Dictator Game – How to Interrupt the Chain of Unfairness
por: Strang, Sabrina, et al.
Publicado: (2016)

Behavioral Intention Promotes Generalized Reciprocity: Evidence From the Dictator Game
por: Sun, Zhongqiang, et al.
Publicado: (2020)

S1P(1)-mTOR axis directs the reciprocal differentiation of T(H)1 and regulatory T cells
por: Liu, Guangwei, et al.
Publicado: (2010)

Use of the mTOR inhibitor everolimus in a patient with multiple manifestations of tuberous sclerosis complex including epilepsy
por: Wheless, James W.
Publicado: (2015)

New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth
por: Dill, Patricia E, et al.
Publicado: (2015)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders
por: Franz, David N., et al.
Publicado: (2017)

Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
por: Śmiałek, Dominika, et al.
Publicado: (2023)

Renal Cell Carcinoma in Tuberous Sclerosis Complex
por: Henske, Elizabeth P., et al.
Publicado: (2021)

Non-canonical functions of the tuberous sclerosis complex-Rheb signalling axis
por: Neuman, Nicole A, et al.
Publicado: (2011)

NLRP3 and mTOR Reciprocally Regulate Macrophage Phagolysosome Formation and Acidification Against Vibrio vulnificus Infection
por: Huang, Xian-Hui, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_oaiv5aq981tk6h5gq9dk18pc4t